Compare HP Inc (HPQ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? HP Inc trades at $30.46 (market cap $27.62B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: HP Inc is far larger — about 3.7× Spyre Therapeutics Inc. Common Stock's market cap, and HP Inc pays a 3.92% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HPQ | SYRE | |
|---|---|---|
Market Cap | $27.62B | $7.52B |
Volume | 12,820,066 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $35.48 | $108.92 |
52-Week Low | $18.20 | $22.18 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $33.79B | $6.52B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $30.46, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains stable cash flow generation ($460M net in 2025) and pays a $0.30 dividend, but faces PC market headwinds with 2027 industry volume declines projected. Valuation appears reasonable with P/E of 11.69 and P/S of 0.48, though negative shareholder equity raises concerns.
The outlook is mixed: attractive valuation and dividend yield support the stock, but PC market challenges and negative equity position create significant risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside potential amid industry uncertainty.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
